Johnson & Johnson (JNJ)vsUFP Technologies Inc (UFPT)
JNJ
Johnson & Johnson
$265.58
-0.29%
HEALTHCARE · Cap: $640.02B
UFPT
UFP Technologies Inc
$277.89
+0.18%
HEALTHCARE · Cap: $2.16B
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 15404% more annual revenue ($97.93B vs $631.64M). JNJ leads profitability with a 21.5% profit margin vs 11.5%. JNJ appears more attractively valued with a PEG of 2.79. UFPT earns a higher WallStSmart Score of 60/100 (C+).
JNJ
Buy59
out of 100
Grade: C
UFPT
Buy60
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-88.9%
Fair Value
$140.57
Current Price
$265.58
$125.01 premium
Intrinsic value data unavailable for UFPT.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 25 in profit
Keeps 22 of every $100 in revenue as profit
Strong operational efficiency at 29.2%
Generating 3.4B in free cash flow
Safe zone — low bankruptcy risk
Conservative balance sheet, low leverage
15.1% revenue growth
Earnings expanding 21.3% YoY
Areas to Watch
Premium valuation, high expectations priced in
Expensive relative to growth rate
Earnings declined 0.9%
Premium valuation, high expectations priced in
Expensive relative to growth rate
Comparative Analysis Report
WallStSmart ResearchBull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 21.5% and operating margin at 29.2%.
Bull Case : UFPT
The strongest argument for UFPT centers on Altman Z-Score, Debt/Equity, Revenue Growth. Revenue growth of 15.1% demonstrates continued momentum.
Bear Case : JNJ
The primary concerns for JNJ are P/E Ratio, PEG Ratio, EPS Growth.
Bear Case : UFPT
The primary concerns for UFPT are P/E Ratio, PEG Ratio.
Key Dynamics to Monitor
JNJ profiles as a mature stock while UFPT is a growth play — different risk/reward profiles.
UFPT carries more volatility with a beta of 1.07 — expect wider price swings.
UFPT is growing revenue faster at 15.1% — sustainability is the question.
JNJ generates stronger free cash flow (3.4B), providing more financial flexibility.
Bottom Line
UFPT scores higher overall (60/100 vs 59/100) and 15.1% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →UFP Technologies Inc
HEALTHCARE · MEDICAL DEVICES · USA
UFP Technologies, Inc. designs and converts foams, films and plastic materials for the medical, automotive, consumer, electronic, industrial, aerospace and defense markets in the United States. The company is headquartered in Newburyport, Massachusetts.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?